News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
The company is working closely with its six manufacturing partners in India
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
